A stress-relief drink is a non-alcoholic beverage built around ingredients marketed for relaxation, mood support or emotional balance. The category is defined by a claimed benefit rather than by a base liquid or a format: a sparkling water with L-theanine, a ready-to-drink tea with lemon balm, a 60 ml wellness shot with ashwagandha and an alcohol-free beer with magnesium all belong to it. That definitional looseness is the single most useful thing to understand about the segment, because it explains both the speed of its growth and the difficulty of comparing two cans side by side.
The commercial context is unambiguous. Stress now ranks as the top wellbeing concern globally, cited by 43% of consumers, ahead of anxiety at 36% and sleep difficulties at 32%, according to Innova Market Insights figures reported by FoodNavigator on 29 July 2026. Relaxation beverages are growing at roughly 19% a year, a pace comparable to brain-health drinks, and are approaching the market share held by gut-health drinks. The parent functional beverage market was valued at USD 151.80 billion in 2025 and is projected at USD 163.84 billion for 2026, on a 7.93% compound annual growth rate through 2031.
What counts as a stress-relief drink, and what does not?
Four ingredient families define the category in 2026: amino acids (L-theanine, GABA), minerals (magnesium in its various salts), botanical adaptogens (ashwagandha, rhodiola, lemon balm, chamomile) and functional fungi (reishi, chaga, lion's mane, turkey tail). A drink belongs to the category when one of these appears on the front of the pack with a relaxation cue attached to it. A chamomile tea bag sold as tea does not; the same chamomile in a canned sparkling beverage sold as a calm ritual does.
Excluded, by construction, are two adjacent things frequently confused with it. Sedative herbal medicines regulated as traditional herbal medicinal products sit under a different legal regime entirely, with a marketing authorisation, a leaflet and a dosage. And alcohol, still the most widely used self-administered relaxant in Europe, is the substance the category is designed to displace at the exact moment of the evening when someone reaches for a drink to change how they feel.
How fast is the category actually growing, and who is buying it?
Growth runs at about 19% annually and the buyer is drinking at home, alone, on an ordinary weekday. Innova consumer data reported in July 2026 shows 45% consume stress-relief drinks at home, 30% treat them as a dedicated moment to themselves, and 23% drink them during work or study. On motivation, 36% want to relax or unwind, 33% specifically seek stress relief and 22% look for mood support.
Those three occasions matter more than the growth rate because they describe a replacement pattern rather than an addition. A drink consumed at home in the evening as a moment to oneself occupies the slot historically held by a glass of wine or a beer. A drink consumed during work or study occupies the slot held by a third coffee. The category is therefore expanding into two different displacement opportunities at once, which is unusual, and it is the reason large beverage groups have entered a segment that start-ups opened.
The surprising number sits in the ingredient data rather than the sales data. Turkey tail mushroom, a species with almost no consumer recognition outside functional-fungi circles, went from two stress-relief beverage launches in 2023 to thirteen in 2025. That is a small absolute number, and that is the point: the category is being built at the edges, by formulators looking for an ingredient that competitors have not yet claimed, rather than by consumers asking for a specific mushroom.
Four ingredient families carry the category: amino acids, minerals, botanical adaptogens and functional fungi. Only two of the four have an authorised European health claim behind them.
Which ingredients survive a clinical trial, and at what dose?
Two ingredients hold reproducible human evidence at a stated dose, and both are unglamorous. L-theanine at 200 mg per day for four weeks reduced scores for depression, trait anxiety and sleep quality in a randomised placebo-controlled crossover trial of 30 healthy adults with a mean age of 48.3 years, with p values of 0.019, 0.006 and 0.013 respectively. A systematic review and meta-analysis of 31 randomised trials covering 1,168 participants found the acute stress effect real but modest.
Ashwagandha has the most-cited cortisol result in the category. A 60-day double-blind placebo-controlled trial in 64 chronically stressed adults, using 300 mg of KSM-66 root extract twice daily, reported a 27.9% fall in serum cortisol against placebo. The number travels widely on packaging; the dose that produced it, 600 mg per day for two months, almost never does. GABA occupies the opposite position: the reviews conclude that evidence on whether orally administered GABA crosses the blood-brain barrier in meaningful quantity remains contradictory, and the mechanism behind reported effects is unknown.
Magnesium is the quiet exception. It is a nutrient rather than a botanical, it has an established reference intake, and its claim is authorised rather than pending. That regulatory position, not its pharmacology, is why magnesium appears on the front of so many 2026 cans.
What can a European label legally claim in 2026?
Almost nothing specific about stress, if the active is a plant. Health claims covering ashwagandha, rhodiola and the bulk of botanical ingredients have sat on hold under Article 13.1 of Regulation (EC) No 1924/2006 since 2013, usable only under the transitional measures of Article 28(5) while EFSA has issued no positive opinion. Magnesium is the counter-example: its contribution to normal psychological function is an authorised claim in the EU register.
The consequence is a labelling grammar that reads oddly once decoded. Brands write around the restriction with mood language that is not a health claim, product names that carry the benefit, and ingredient lists that do the arguing. Meanwhile the underlying legal status of the ingredients themselves is moving. Denmark banned ashwagandha in food supplements in 2023, the first EU member state to do so, following a 2020 Technical University of Denmark assessment that could not establish a safe intake level. On 14 July 2026, ashwagandha specialists convened at the European Parliament to discuss the botanical's future regulatory status across the bloc.
Functional fungi face a separate gate. Under the EU novel food framework, reishi fruiting body and its hot water extract are treated as having a pre-1997 consumption history and need no authorisation, while dehydrated lion's mane mycelium powder is classed as novel and does. Cordyceps in a beverage, as opposed to a supplement, generally requires pre-market authorisation. Kava remains unauthorised as a food in the EU and the UK. The mushroom or plant printed on the can therefore determines whether the product may legally exist, before any question of whether it works.
Which brands built the European shelf?
Three British companies shaped what a European stress-relief drink looks like. Three Spirit, founded in London (United Kingdom) in 2018, sells botanical elixirs positioned by mood rather than by flavour, including a Nightcap built on valerian root and lemon balm. Impossibrew, founded in 2019, applied the logic to alcohol-free beer with a blend of L-theanine and ashwagandha, and raised GBP 1.5 million on Crowdcube in 2025 from more than 1,200 investors, overfunding a GBP 500,000 target by 315%. Trip began in CBD and moved to a broader relaxation position, launching its Mindful Blend in 2024 with lion's mane, magnesium and ashwagandha.
What the three share is a formulation signature rather than a flavour house style: a small number of named actives, printed on the front, in a format designed for one serving. What they do not share is a common dosage standard, which is why the category still cannot be compared the way an alcohol-free beer can be compared by ABV and IBU.
Comparison: four ingredient families against the evidence
| Ingredient family | Studied dose (per day) | EU claim status (2026) | Strength of human evidence |
|---|---|---|---|
| L-theanine (amino acid) | 200 mg, 4 weeks | No authorised stress claim | Meta-analysed across 31 trials, modest and consistent |
| Magnesium (mineral) | Reference intake 300 to 400 mg | Authorised: contributes to normal psychological function | Established as a nutrient, not as an acute stress treatment |
| Ashwagandha KSM-66 (botanical) | 600 mg, 60 days | On hold since 2013; banned in supplements in Denmark | Cortisol reduction of 27.9% in one 64-subject trial |
| Reishi and chaga (functional fungi) | No consensus beverage dose | Fruiting body not novel; some extracts require authorisation | Traditional use documented, clinical evidence thin |
| GABA (amino acid) | 100 to 200 mg in most products | No authorised stress claim | Blood-brain barrier passage contested, mechanism unknown |
Sources
- FoodNavigator, Stress-relief drinks drive next wave of functional beverage growth, 29 July 2026, citing Innova Market Insights consumer and launch data.
- Mordor Intelligence, Functional Beverage Market Size and Share Analysis, 2026 edition.
- Hidese et al., Effects of L-Theanine Administration on Stress-Related Symptoms and Cognitive Functions in Healthy Adults: A Randomized Controlled Trial, Nutrients, 2019.
- Systematic review and meta-analysis of 31 randomised trials of L-theanine (n = 1,168), Molecular Psychiatry, 2026.
- Chandrasekhar et al., A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults, Indian Journal of Psychological Medicine, 2012.
- Regulation (EC) No 1924/2006 on nutrition and health claims, Articles 13.1 and 28(5); EU Register on nutrition and health claims, European Commission.
- Technical University of Denmark risk assessment of ashwagandha, 2020, and Danish Veterinary and Food Administration decision, 2023.
- NutraIngredients, Ashwagandha armed with critical safety data as industry anticipates Europe-wide assessment, 16 July 2026.
- EU Novel Food Catalogue, entries for Ganoderma lucidum, Hericium erinaceus and Cordyceps, European Commission, consulted September 2026.
- Boonstra et al., Neurotransmitters as food supplements: the effects of GABA on brain and behavior, Frontiers in Psychology, 2015.
The stress-relief drink is the first functional category in which the regulatory question arrives before the efficacy question. A formulator choosing between reishi and cordyceps is choosing between a legal ingredient and one that needs authorisation; a brand printing a cortisol figure is quoting a 600 mg supplement trial on a can that may contain a fraction of that. For a reader trying to judge a product, the shortest reliable test is whether the pack states a milligram figure for its named active. Most do not, and that absence is the most informative thing on the label.